Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity

Analytical Biochemistry

Volumn 451, Issue 1, 2014, Pages 1-3

  Wilkins, Owen M ^a   Downey, Sondra L ^a   Weyburne, Emily S ^a   Williams, David A ^a   Mirabella, Anne C ^a   Overkleeft, Herman S ^b   Kisselev, Alexei F ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Protease; Proteasome; Ubiquitin

Indexed keywords

CELL CULTURE; SUBSTRATES;

CELL LINES; CELL-BASED ASSAYS; LUNG CANCER CELLS; PROTEASE; PROTEASOME INHIBITORS; PROTEASOMES; TRYPSIN-LIKE ACTIVITIES; UBIQUITIN;

CELLS;

PROTEASOME; PROTEASOME INHIBITOR; TRYPTASE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEASOME GLO ASSAY;

PROTEASE; PROTEASOME; UBIQUITIN;

CELL LINE, TUMOR; FLUORESCENT DYES; HELA CELLS; HUMANS; LUMINESCENT MEASUREMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; SUBSTRATE SPECIFICITY; TRYPSIN;

EID: 84896865461     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2014.01.009     Document Type: Article

References (10)

1. A.F. Kisselev, W.A. van der Linden, and H.S. Overkleeft Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 19 2012 99 115
2. A.F. Kisselev, and A.L. Goldberg Measuring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates Methods Enzymol. 398 2005 364 378 (Pubitemid 41578898)
3. A.F. Kisselev, A. Callard, and A.L. Goldberg Importance of different active sites in protein breakdown by 26S proteasomes and the efficacy of proteasome inhibitors varies with the protein substrate J. Biol. Chem. 281 2006 8583 8590
4. M. Britton, M.M. Lucas, S.L. Downey, M. Screen, A.A. Pletnev, M. Verdoes, R.A. Tokhunts, O. Amir, A.L. Goddard, P.M. Pelphrey, D.L. Wright, H.S. Overkleeft, and A.F. Kisselev Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites Chem. Biol. 16 2009 1278 1289
5. R.A. Moravec, M.A. O'Brien, W.J. Daily, M.A. Scurria, L. Bernad, and T.L. Riss Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format Anal. Biochem. 387 2009 294 302
6. T.B. Shabaneh, S.L. Downey, A.L. Goddard, M. Screen, M.M. Lucas, A. Eastman, and A.F. Kisselev Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib PLoS One 8 2013 e56132
7. M. Verdoes, B.I. Florea, V. Menendez-Benito, M.D. Witte, W.A. van der Linden, A.M.C.H. van den Nieuwendijk, T. Hofmann, C. Berkers, F.W.B. van Leeuwen, T.A. Groothuis, M.A. Leeuwenburgh, H. Ovaa, J. Neefjes, D.V. Filippov, G.A. van der Marel, N.P. Dantuma, and H.S. Overkleeft A fluorescent broad spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo Chem. Biol. 13 2006 1217 1226 (Pubitemid 44750733)
8. M. Verdoes, L.I. Willems, W.A. van der Linden, B.A. Duivenvoorden, G.A. van der Marel, B.I. Florea, A.F. Kisselev, and H.S. Overkleeft A panel of subunit-selective activity-based proteasome probes Org. Biomol. Chem. 8 2010 2719 2727
9. A.C. Mirabella, A.A. Pletnev, S.L. Downey, B.I. Florea, T.B. Shabaneh, M. Britton, M. Verdoes, D.V. Filippov, H.S. Overkleeft, and A.F. Kisselev Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib Chem. Biol. 18 2011 608 618
10. M. Screen, M. Britton, S.L. Downey, M. Verdoes, M.J. Voges, A.E. Blom, P.P. Geurink, M.D. Risseeuw, B.I. Florea, W.A. van der Linden, A.A. Pletnev, H.S. Overkleeft, and A.F. Kisselev Nature of pharmacophore influences active site specificity of proteasome inhibitors J. Biol. Chem. 285 2010 40125 40134